WHO clears BE's nopv2 production expansion

Hyderabad: Hyderabad-based Biological E (BE) Limited has secured Phase II Pre-Qualification (PQ) from the World Health Organization (WHO) for its Novel Oral Polio Vaccine type 2 (nOPV2), enabling full end-to-end manufacturing at a single integrated facility. The approval covers both drug substance and drug product manufacturing, expanding on the Phase I PQ granted in June 2024. The company has already supplied 700 million doses of nOPV2 to global stockpiles supporting vaccination drives against circulating vaccine-derived poliovirus type 2 (cVDPV2). The milestone strengthens global outbreak response capacity by adding integrated WHO-qualified production, enhancing supply resilience and rapid deployment during emergencies. Biological E Managing Director Mahima Datla said faster response and reliable supply are critical to halting transmission during outbreaks.